Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Scholar Rock Holding Stock

Price
Target price
€40.40

€40.40

1.000%
0.4
1.000%
€41.73
 
07:30 / Tradegate WKN: A2JMQW / Symbol: SRRK / Name: Scholar Rock / Stock / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Scholar Rock Holding in the next few years
Wizard

Description Scholar Rock

Scholar Rock is a publicly listed biotechnology company that focuses on developing medicines for patients suffering from serious diseases. Its symbol on the stock market is SRRK. The company is based in Massachusetts, USA, and was founded in 2012. Scholar Rock’s research focuses on discovering and developing drugs that target molecular mechanisms that enable the body to heal itself. It has developed a platform technology that targets a group of proteins known as growth factors, which play a key role in cell signaling and tissue repair. Scholar Rock’s lead drug candidate is SRK-015, which is currently being studied for the treatment of spinal muscular atrophy (SMA), a rare and devastating genetic disease that affects the muscles used for movement. The company has several other drug candidates in pre-clinical development, focusing on areas such as cancer, fibrosis, and neurodegenerative diseases.

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Scholar Rock Holding is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Scholar Rock

sharewise wants to provide you with the best news and tools for Scholar Rock, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss


Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and additional severe and

BusinessWire_EN 
0 18.06.25